AbCellera Biologics (NASDAQ:ABCL) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of AbCellera Biologics (NASDAQ:ABCL) in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $7.00 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 52.51% from the stock’s current price.

Other research analysts have also issued research reports about the company. Wall Street Zen raised AbCellera Biologics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research report on Monday, April 20th. Finally, JonesTrading initiated coverage on shares of AbCellera Biologics in a report on Friday, April 10th. They set a “buy” rating and a $11.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.17.

AbCellera Biologics Price Performance

Shares of NASDAQ:ABCL opened at $4.59 on Tuesday. The stock has a market cap of $1.40 billion, a P/E ratio of -9.37 and a beta of 1.02. AbCellera Biologics has a 1-year low of $1.94 and a 1-year high of $6.51. The firm has a fifty day moving average price of $3.60 and a 200 day moving average price of $3.86.

AbCellera Biologics (NASDAQ:ABCL) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.15. AbCellera Biologics had a negative net margin of 198.37% and a negative return on equity of 15.05%. The company had revenue of $44.85 million for the quarter, compared to analysts’ expectations of $6.31 million. Sell-side analysts expect that AbCellera Biologics will post -0.89 EPS for the current fiscal year.

Institutional Investors Weigh In On AbCellera Biologics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hollencrest Capital Management purchased a new stake in shares of AbCellera Biologics during the 3rd quarter worth about $25,000. AssuredPartners Investment Advisors LLC acquired a new position in AbCellera Biologics during the fourth quarter valued at approximately $34,000. OneDigital Investment Advisors LLC acquired a new position in AbCellera Biologics during the third quarter valued at approximately $52,000. Insigneo Advisory Services LLC acquired a new stake in shares of AbCellera Biologics in the third quarter worth $52,000. Finally, Voleon Capital Management LP purchased a new position in shares of AbCellera Biologics in the 3rd quarter valued at $56,000. 61.42% of the stock is currently owned by institutional investors and hedge funds.

AbCellera Biologics Company Profile

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.